#USA #Chicago #Liquid Biopsy #Belay Diagnostics #Leptomeningeal Disease

Introduction

Leptomeningeal disease (LMD) poses one of the most significant challenges in neuro-oncology today. Diagnosing LMD can be incredibly difficult, as MRI machines often yield normal or inconclusive results—estimates indicate that this happens in 20 to 30% of confirmed cases. In approximately one-third of instances, CSF cytology also misses the diagnosis during initial testing. This presents a major hurdle for clinicians who need to make timely and accurate decisions for their patients.

Study Overview

A groundbreaking peer-reviewed study published in the journal Diagnostics has shed light on a promising solution: measuring the variant allele frequency (VAF) from tumor-derived DNA found in cerebrospinal fluid (CSF) using the Summit™ liquid biopsy assay. Such approaches could help clinicians better diagnose and monitor treatment responses for patients suspected of having leptomeningeal disease.

The study reviewed 118 CSF specimens obtained from patients who had a provisional diagnosis of metastatic central nervous system (CNS) cancer, including cases related to breast and lung cancers, among others. Remarkably, the Summit™ assay detected clinically relevant genomic alterations in all examined specimens across 22 of the 32 genes on its panel, such as TP53, EGFR, KRAS, and PIK3CA. This resulted in the identification of patients who might have slipped through the cracks of traditional diagnostic methods.

Key Findings

One of the major revelations was the identification of a VAF threshold at 5%. This metric emerged as potentially meaningful for confirming diagnoses of LMD. In the analysis, about 69% of patients diagnosed with LMD had VAFs exceeding this threshold, while most patients suffering from parenchymal metastases or those whose LMD was not confirmed generally presented VAFs below the 5% mark.

Interestingly, in cases where MRI imaging and cytology provided inconclusive information, a raised VAF led to further investigations, ultimately confirming LMD in some cases. For ten additional patients initially thought to have parenchymal metastases or suspected LMD, elevated VAFs that surpassed 5% were later shown to correlate with confirmed LMD following either clinical or pathological follow-up.

In terms of treatment monitoring, the study pointed to the efficacy of the Summit™ assay in tracking changes in VAF over time. For those undergoing treatment, half of the patients involved in repeat testing experienced a decrease or absence of VAF, which aligned with clinical improvements. Conversely, one patient exhibited a rising VAF, likely indicative of disease progression, while in three cases, new variants appeared upon repeat testing, suggesting an evolutionary change within the tumors.

Implications for the Future

Doctor Nancy Ann O. Bush, a Clinical Director in Neuro-Oncology, described this study as a significant turning point in neuro-oncology. The liquid biopsy technology used in this study allows for ongoing monitoring of the tumor's molecular evolution. Such insights can empower clinicians to detect clonal evolution or potential treatment resistance before observable changes appear in radiographic images, thereby bridging the gap between biological changes and timely clinical intervention.

Conclusion

This study lays the groundwork for larger-scale prospective validation, focusing on tumor-specific cohorts. As the medical community moves forward, technologies like the Summit™ liquid biopsy assay may redefine how we approach complex neuro-oncology cases and improve outcomes for patients faced with challenging conditions such as leptomeningeal disease.

For complete study details, visit Belay Diagnostics.